Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer

被引:16
作者
Bandini, Marco [1 ,2 ,3 ]
Marchioni, Michele [3 ,4 ]
Preisser, Felix [3 ,5 ]
Zaffuto, Emanuele [1 ,2 ]
Tian, Zhe [3 ]
Tilki, Derya [5 ]
Montorsi, Francesco [1 ,2 ]
Shariat, Shahrokh F. [6 ]
Saad, Fred [3 ]
Briganti, Alberto [1 ,2 ]
Karakiewicz, Pierre I. [3 ]
机构
[1] IRCCS Osped San Raffaele, Div Oncol, Unit Urol, URI, Via Olgettina 60, I-20132 Milan, MI, Italy
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[4] Univ G dAnnunzio, SS Annunziata Hosp, Dept Urol, Chieti, Italy
[5] Univ Med Ctr Hamburg Eppendorf, Martini Klin, Hamburg, Germany
[6] Med Univ Vienna, Dept Urol, Vienna, Austria
关键词
Prostate cancer; Radical prostatectomy; External beam radiotherapy; Locally advanced disease; SEER program; EXTERNAL-BEAM RADIOTHERAPY; SINGLE-INSTITUTION; REGRESSION; THERAPY;
D O I
10.1007/s00345-018-2310-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa. Methods Within the SEER database (2004-2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses. Results Ten-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2%) than RP (8.1 and 10.4%) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP. Conclusions CSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses.
引用
收藏
页码:1399 / 1407
页数:9
相关论文
共 26 条
[11]   Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study [J].
Hager, B. ;
Kraywinkel, K. ;
Keck, B. ;
Katalinic, A. ;
Meyers, M. ;
Zeissig, S. R. ;
Scheufele, R. ;
Wirth, M. P. ;
Huber, J. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (01) :61-66
[12]   Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy [J].
Hsu, Chao-Yu ;
Wildhagen, Mark F. ;
Van Poppel, Hein ;
Bangma, Chris H. .
BJU INTERNATIONAL, 2010, 105 (11) :1536-1540
[13]   Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy [J].
Kupelian, PA ;
Elshaikh, M ;
Reddy, CA ;
Zippe, C ;
Klein, EA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3376-3385
[14]   Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review [J].
Lardas, Michael ;
Liew, Matthew ;
van den Bergh, Roderick C. ;
De Santis, Maria ;
Bellmunt, Joaquim ;
Van den Broeck, Thomas ;
Cornford, Philip ;
Cumberbatch, Marcus G. ;
Fossati, Nicola ;
Gross, Tobias ;
Henry, Ann M. ;
Bolla, Michel ;
Briers, Erik ;
Joniau, Steven ;
Lam, Thomas B. ;
Mason, Malcolm D. ;
Mottet, Nicolas ;
van der Poel, Henk G. ;
Rouviere, Olivier ;
Schoots, Ivo G. ;
Wiegel, Thomas ;
Willemse, Peter-Paul M. ;
Yuan, Cathy Yuhong ;
Bourke, Liam .
EUROPEAN UROLOGY, 2017, 72 (06) :869-885
[15]   Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification [J].
Leyh-Bannurah, Sami-Ramzi ;
Budaeus, Lars ;
Zaffuto, Emanuele ;
Pompe, Raisa S. ;
Bandini, Marco ;
Briganti, Alberto ;
Montorsi, Francesco ;
Schiffmann, Jonas ;
Shariat, Shahrokh F. ;
Fisch, Margit ;
Chun, Felix ;
Huland, Hartwig ;
Graefen, Markus ;
Karakiewicz, Pierre I. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (02) :81.e17-81.e24
[16]   The use of group sequential designs withcommon competing risks tests [J].
Logan, Brent R. ;
Zhang, Mei-Jie .
STATISTICS IN MEDICINE, 2013, 32 (06) :899-913
[17]   20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer [J].
Mitchell, Christopher R. ;
Boorjian, Stephen A. ;
Umbreit, Eric C. ;
Rangel, Laureano J. ;
Carlson, Rachel E. ;
Karnes, R. Jeffrey .
BJU INTERNATIONAL, 2012, 110 (11) :1709-1713
[18]   Propensity score matching and randomization [J].
Mnatzaganian, George ;
Davidson, David C. ;
Hiller, Janet E. ;
Ryan, Philip .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2015, 68 (07) :760-768
[19]   Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013 [J].
Noone, Anne-Michelle ;
Cronin, Kathleen A. ;
Altekruse, Sean F. ;
Howlader, Nadia ;
Lewis, Denise R. ;
Petkov, Valentina I. ;
Penberthy, Lynne .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (04) :632-641
[20]   Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31 [J].
Pilepich, MV ;
Winter, K ;
Lawton, CA ;
Krisch, RE ;
Wolkov, HB ;
Movsas, B ;
Hug, EB ;
Asbell, SO ;
Grignon, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05) :1285-1290